Recruiting Clinical Trials

Displaying 51 - 60 of 245 result(s)
Study Title Condition Phase Location
OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration Neovascular Age-related Macular Degeneration (nAMD) Not Given
  • Country: 
    Germany
A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Pa ... Acute Myeloid Leukemia Phase 1, Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Hong Kong
  • Country: 
Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity Retinopathy of Prematurity Not Given
  • Country: 
    Korea, Republic of
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-m ... FLT3-mutated Acute Myeloid Leukemia Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Czech Republic
  • Country: 
A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors Leukemia, Chronic Myelogenous Phase 2
  • Country: 
    China
Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis Multiple Sclerosis Not Given
  • Country: 
    United States
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer) Non-small Cell Lung Cancer Not Given
  • Country: 
    Japan
Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Italy
A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-relat ... Neovascular Age-related Macular Degeneration Phase 4
  • Country: 
    United States
  • Country: 
    Spain